Basel, April 8, 2020 — Patient safety is at the heart of everything we do. Whenever adverse events are reported, we take them seriously and investigate them thoroughly.

As part of its safety surveillance program, Novartis has been actively evaluating post-marketing cases reported as severe vision loss, retinal artery occlusion and/or vasculitis with Beovu^® (brolucizumab). We have been working closely with the reporting physicians and retina specialists to get their perspective and collect the relevant clinical and imaging data in a manner compliant with …